Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

PLRX vs LYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PLRX Captures Overall Composite Edge (39.0 SELL vs 52.2 HOLD), While LYRA Leads 3–2 on Growth & Valuation Pillars

PLRX Overall Winner 6-Pillar Tally: PLRX 2 – 3 LYRA (1 Tie) Matrix Metrics: PLRX 4 – 3 LYRA

As of Nov 17, 2026, Pliant Therapeutics, Inc. (PLRX) captures the overall head-to-head institutional edge over Lyra Therapeutics, Inc. (LYRA) on higher Unified Composite conviction (39.0/100 SELL vs. 52.2/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality, Options & Positioning), while LYRA wins 3–2 across the 6-pillar growth and valuation breakdown. PLRX trades at $0.66 (N/M Forward P/E, 0.0% operating margin) versus LYRA at $0.49 (N/M Forward P/E, -25032.0% operating margin).

  • Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. PLRX 39.0/100 SELL), PLRX captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (-100.0% vs. -87.2% YoY).
  • Technical & Structure Timing Caution: PLRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.7); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PLRX vs LYRA
PLRX NASDAQ Head-to-Head Winner
Pliant Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.66
-5.16% 1D
Market Cap $43.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.93β · 37% Vol
Unified Composite Score
39.0 / 100 SELL
Tech 25.0 Fund 43.0 Flow 63.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.5%), weak momentum, RSI 20
RSI-14: 19.7 · SMA20: $0.81 · SMA50: $0.96
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (PLRX 2 – 3 LYRA)

Columns: Metric · PLRX · LYRA
1. Valuation Multiples LYRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 3.9x
2. Growth & Scale LYRA
Revenue Growth (YoY) -100.0% -87.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $600,000
Market Cap $43.2M $2.3M
3. Profitability & Quality PLRX
Gross Margin N/A N/A
Operating Margin 0.0% -25032.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -50.3% -404.5%
4. Balance Sheet & Cash Flow LYRA
Cash Generation (TTM) -$71M -$32M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.9M Net Debt (0.20x D/E) -404.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PLRX
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 12.8% (4th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PLRX (4) vs LYRA (3)
Institutional Metric PLRX LYRA Criterion Row Edge
Market Capitalization
Scale
$43.2M $2.3M Larger Scale PLRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% -87.2% Higher Growth LYRA
Operating Margin (TTM)
Profitability
0.0% -25032.0% Higher Margin PLRX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-50.3% -404.5% Higher ROE PLRX
52-Week Range Position
Momentum
0% ($1–$2) 1% ($0–$38) Stronger Trend LYRA
Beta / 30D Volatility
Risk Regime
0.93β · 37% Vol 0.33β · 248% Vol Lower Realized Risk PLRX
Unified Institutional Score
Composite Signal
39.0 / 100 (SELL) 52.2 / 100 (HOLD) Higher Composite LYRA
Trailing 12M Revenue (USD)
Operating Scale
N/A $600,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$71M ($3.9M Net Debt (0.20x D/E)) -$32M EBITDA (-404.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLRX +78.43 pp
PLRX: +15.93% · LYRA: -62.5%
3M Horizon PLRX +86.86 pp
PLRX: -0.76% · LYRA: -87.62%
6M Horizon PLRX +65.12 pp
PLRX: -22.02% · LYRA: -87.14%
1Y Horizon PLRX +65.12 pp
PLRX: -22.02% · LYRA: -87.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PLRX Revenue LYRA Revenue PLRX Op. Margin LYRA Op. Margin Margin Leader
FY2019 $60M N/A -2.2% N/A PLRX
FY2020 $40M N/A -99.6% N/A PLRX
FY2021 $10M $0M -1288.1% -15303.5% PLRX
FY2022 $10M $0M -1313.4% -4131.0% PLRX
FY2023 $0M $0M -11654.7% -4308.1% LYRA
FY2024 N/A $0M N/A -6280.8% LYRA
FY2025 N/A $0M N/A -7794.5% LYRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PLRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 12.8%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact PLRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PLRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $43.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PLRX vs LYRA Key Questions & Quantitative Answers

As of Nov 17, 2026, Pliant Therapeutics, Inc. (PLRX) captures the overall head-to-head institutional edge over Lyra Therapeutics, Inc. (LYRA) on higher Unified Composite conviction (39.0/100 SELL vs. 52.2/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality, Options & Positioning), while LYRA wins 3–2 across the 6-pillar growth and valuation breakdown. PLRX trades at $0.66 (N/M Forward P/E, 0.0% operating margin) versus LYRA at $0.49 (N/M Forward P/E, -25032.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. PLRX 39.0/100 SELL), PLRX captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (-100.0% vs. -87.2% YoY). Technical & Structure Timing Caution: PLRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.7); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LYRA leads the Growth & Scale pillar: PLRX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), PLRX cumulative revenue shifted -83.3% while LYRA shifted N/A. In operating R&D and SG&A reinvestment, PLRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.

LYRA screens cheaper on headline valuation multiples. PLRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLRX (-50.3% ROE) versus LYRA (-404.5% ROE) capital efficiency.

In options market volatility and institutional positioning, PLRX carries 12.8% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.93β · 37% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.